Palvella Therapeutics (PVLA) Notes Payables (2024 - 2025)
Palvella Therapeutics' (PVLA) quarterly Notes Payables came in at $2.2 million in Q4 2025, up 11.02% year-on-year from $2.0 million in Q4 2024, and down 0.9% on a QoQ basis from $2.2 million in Q3 2025.
Palvella Therapeutics (PVLA) Notes Payables (2024 - 2025) Analysis & Trends
Palvella Therapeutics (PVLA) has 2 years of Notes Payables data on file, last reported at $2.2 million in Q4 2025.
- On a quarterly basis, Notes Payables rose 11.02% year-over-year to $2.2 million in Q4 2025; TTM through Dec 2025 was $2.2 million, a 11.02% increase from a year earlier, with the FY2025 full-year figure at $2.2 million, up 11.02% from the prior year.
- Notes Payables for Q4 2025 stood at $2.2 million, down from $2.2 million in the prior quarter.
- Over the last five years, Notes Payables for PVLA reached as high as $2.2 million in Q3 2025 and fell as low as $2.0 million in Q4 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - |
| 10 | Palvella Therapeutics | 318.78 Mn | 56.92 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 2.20 Mn |
| Sep 30, 2025 | 2.22 Mn |
| Jun 30, 2025 | 1.98 Mn |
| Mar 31, 2025 | 1.98 Mn |
| Dec 31, 2024 | 1.98 Mn |